Patients suffering from severe emphysema have few good options. Once inhaled medications cease to be effective, highly invasive lung volume reduction surgery or lung transplantation are the options that are available only to select patients. Pulmonx Corp. has gained an FDA approval as part of the breakthrough device designation program for its Zephyr endobronchial valve system that offers a minimally invasive solution that's precisely targeted to each individual patient. Read More
